The rise and fall of the atypical antipsychotics

British Journal of Psychiatry

Volumn 199, Issue 4, 2011, Pages 266-268

  Kendall, Tim ^a  

^a ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; IMIPRAMINE; PLACEBO; RISPERIDONE;

AGRANULOCYTOSIS; CLINICAL PRACTICE; DRUG INDUSTRY; DRUG MARKETING; DRUG MEGADOSE; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FUNDING; HUMAN; MENTAL PATIENT; NEUROPROTECTION; PSYCHIATRIST; REMISSION; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLOZAPINE; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 80053425605     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.083766     Document Type: Review

References (16)

1. Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, et al. Clozapine v. chlorpromazine in treatment-naive, first-episode schizophrenia: 9-year randomised clinical trial. Br J Psychiatry 2011; 199: 281-8.
2. Spielmans, GI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethic Inq 2010; 7: 13-29.
3. Leucht S Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict. Psychol Med 2009; 39: 1591-602.
4. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (updated edition). British Psychological Society and Royal College of Psychiatrists, 2010.
5. Elkes J, Elkes C. Effect of chlorpromazine on the behaviour of chronically overactive psychotic patients. BMJ 1954; 2: 560-5.
6. Kerwin, RW. Clozapine: back to the future for schizophrenia research. Lancet 1995; 345: 1063-4.
7. Hippius H. The history of clozapine. Psychopharmacology 1989; 99: S3-5. (Pubitemid 19244131)
8. Healy D. The Creation of Psychopharmacology. Harvard University Press, 2002.
9. Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685-93. (Pubitemid 18076615)
10. National Institute for Clinical Excellence. Guidance on Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal no. 43. NICE, 2002.
11. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 321: 1371-6.
12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23. (Pubitemid 41345943)
13. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87. (Pubitemid 44498387)
14. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
15. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341-5.
16. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008; 358: 252-60.